Skip to content

A population pharmacokinetic/pharmacodynamic study of liposomal bupivacaine receiving thoracic paravertebral analgesia after thoracic surgery

Study of the efficacy and safety of bupivacaine liposome in the treatment of thoracic paravertebral analgesia and population pharmacokinetics/pharmacodynamics

Status
Recruiting
Phases
Phase 4
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2500099289
Enrollment
Unknown
Registered
2025-03-20
Start date
2024-12-01
Completion date
Unknown
Last updated
2025-03-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acute postoperative chest pain

Interventions

The group of bupivacaine liposomal:Thoracic paravertebral analgesia with liposomal bupivacaine

Sponsors

Beijing Chest Hospital Affiliated to Capital Medical University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to No maximum

Inclusion criteria

Inclusion criteria: 1: American Society of Anesthesiologists (ASA) classification: I-III; 2: Age> 18; 3: There is no restriction on gender; 4: Undergoing elective thoracoscopic lobectomy under general anesthesia.

Exclusion criteria

Exclusion criteria: 1: Refusal to receive PVB or PCIA treatment; 2: Previous anatomical variation of the spine, history of chronic pain; 3: History of alcoholism, opioid abuse; 4: Those who are allergic to local anesthetics or are intolerant to general anesthesia; 5: Abnormal liver and kidney function and coagulation function; 6: Patients with severe cardiovascular and cerebrovascular diseases (myocardial infarction, atrioventricular block, etc.) or abnormal heart rhythm (heart rate100 beats/min, non-sinus heart rate); 7: Pregnant or lactating females, those who have a birth plan within half a year, and who are unwilling or unable to take effective contraceptive measures; 8: Those who are unable to cooperate with pain assessment, such as mental abnormalities or paresthesias; 9: The patient voluntarily requested to withdraw from the study.

Design outcomes

Primary

MeasureTime frame
Pharmacokinetic parameters of bupivacaine liposome population;

Secondary

MeasureTime frame
Sensory block extent;Current Perception Threshold;Pain Perception Threshold;

Countries

China

Contacts

Public ContactLiu Wei

Beijing Chest Hospital Affiliated to Capital Medical University

lw1200@sina.com+86 136 2115 3330

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026